790305-05-4

Basic information

• Product Name: ITMN 4077
• Synonyms: ITMN 4077;t - butyl (2R,6S,13aS,14aR,16aS,Z) - 14a - (cyclopropylsulfonylcarbamoyl) - 2 - hydroxy - 5,16 - dioxo - 1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a - hexadecahydrocyclopropa[e]pyrrolo[1,2 - a][1,4]diazacyclopentadecin - 6 - ylcarbamate
• CAS NO: 790305-05-4
• Molecular Formula: C₂₆H₄₀N₄O₈S
• Molecular Weight: 568.6828
• Mol File: 790305-05-4.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 4.44±0.60(Predicted)
• CAS DataBase Reference: ITMN 4077(CAS DataBase Reference)
• NIST Chemistry Reference: ITMN 4077(790305-05-4)
• EPA Substance Registry System: ITMN 4077(790305-05-4)

Safety Data

• Hazardous Substances Data: 790305-05-4(Hazardous Substances Data)

Usage

General Description

ITMN 4077 is a small molecule drug that was developed as a potential therapeutic for the treatment of viral infections, particularly in the context of respiratory syncytial virus and hepatitis C. It belongs to the class of drugs known as protease inhibitors, which work by targeting and inhibiting specific viral enzymes necessary for viral replication. ITMN 4077 has shown promising activity in preclinical studies, with the potential to inhibit viral replication and reduce infection severity. However, further research and clinical trials are needed to fully assess its safety and efficacy in human patients.

Upstream product

• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 669008-08-6 (2S,4R)-tert-butyl 2-((trans)-1-(ethoxycarbonyl)-2-vinylcyclopropylcarbamoyl)-4-hydroxypyrrolidine-1-carboxylate 
• 259214-54-5 ethyl (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 1233370-50-7 (1S,4R,6S,14S,18R)-14-tert-butoxycarbonylamino-2,15-dioxo-18-triisopropylsilanyloxy-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid ethyl ester 
• 1233370-51-8 (1S,4R,6S,14S,18R)-14-tert-butoxycarbonylamino-2,15-dioxo-18-triisopropylsilanyloxy-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid 
• 862119-83-3 (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester 
• 552335-45-2 (1R,2S)-ethyl 1-((2S,4R)-1-((S)-2-(((tert-butoxy)carbonyl)amino)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxamido)-2-vinylcyclopropanecarboxylate 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 213316-49-5 (1RS,2SR)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 300831-21-4 (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 790305-01-0 1-{[1-(2-tert-butoxycarbonylamino-non-8-enoyl)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 552335-44-1 (1R,2S)-ethyl 1-((2S,4R)-1-((S)-2-(((tert-butoxy)carbonyl)amino)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxamido)-2-vinylcyclopropanecarboxylate 
• 552335-47-4 1-(2(S)-tert-butoxycarbonylamino-non-8-enoyl)-4(R)-hydroxy-pyrrolidine-2(S)-carboxylic acid 

Downstream Products

• 1029259-57-1 C₃₂H₄₄N₄O₈S 
• 1029259-59-3 C₃₈H₄₈N₄O₈S 

Relevant articles and documents

Macrocyclic hepatitis C serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.